Dendritic cells transduced with an adenovirus vector encoding interleukin-12 are a potent vaccine for invasive pulmonary aspergillosis

Genes and Immunity

Volumn 6, Issue 2, 2005, Pages 103-114

  Shao, C ^a   Qu, Jiemingqu ^a   He, L ^a   Zhang, Y ^b   Wang, J ^b   Zhou, H ^a   Wang, Y ^b   Liu, X ^b  

^a FUDAN UNIVERSITY   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Adenovirus; Dendritic cells; Gene therapy; Invasive pulmonary aspergillosis

Indexed keywords

ADENOVIRUS VECTOR; COMPLEMENTARY DNA; DENDRITIC CELL VACCINE; GAMMA INTERFERON; INTERLEUKIN 12;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; ASPERGILLUS FUMIGATUS; CELL STRUCTURE; CONIDIUM; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DRUG POTENCY; FUNGAL DETECTION; GENETIC ENGINEERING; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEAT; IMMUNE RESPONSE; LUNG ASPERGILLOSIS; LUNG PARENCHYMA; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; SURVIVAL RATE; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ADOPTIVE TRANSFER; ANIMALS; ASPERGILLOSIS, ALLERGIC BRONCHOPULMONARY; ASPERGILLUS FUMIGATUS; DENDRITIC CELLS; FUNGAL VACCINES; GENE THERAPY; INTERLEUKIN-12; MICE; MICE, INBRED BALB C;

ADENOVIRIDAE; ANIMALIA; ASPERGILLUS; ASPERGILLUS FUMIGATUS;

EID: 15944371848     PISSN: 14664879     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gene.6364167     Document Type: Article

References (56)

1. Cenci E, Mencacci A, Bacci A, Bistoni F, Kurup, VP, Romani L. T cell vaccination in mice with invasive pulmonary aspergillosis. J Immunol 2000; 165: 381-388.
2. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26: 781-805.
3. Cenci E, Mencacci A, Fè d'Ostiani C et al. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis 1998; 178: 1750-1760.
4. Mehrad B, Strieter RM, Standiford TJ. Role of TNF-α in pulmonary host defense in murine invasive aspergillosis. J Immunol 1999; 162: 1633-1640.
5. Cenci E, Mencacci A, Del Sero G et al. IL-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type 1 responses. J Infect Dis 1999; 180: 1957-1968.
6. Del Sero G, Mencacci A, Cenci E et al. Antifungal type 1 responses are upregulated in IL-10-deficient mice. Microbes Infect 1999; 14: 1169-1180.
7. Cenci E, Mencacci A, Del Sero G et al. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I responses. J Infect Dis 1999; 180: 1957-1968.
8. Austyn JM. Dendritic cells. Curr Opin Hematol 1998; 5: 3-15.
9. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252.
10. Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
11. Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997; 15 297-322.
12. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184: 747-752.
13. Sousa CR, Hieny S, Scharton-Kersten T et al. In vivo microbial stimulation induces rapid CD40 ligand-independent production of interleukin-12 by dendritic cells and their redistribution to T cell areas. J Exp Med 1997; 186: 1819-1829.
14. Claudia M, Bacci A, Silvia B, Gaziano R, Spreca A, Romani L. The interaction of fungi with dendritic cells: implication for Th immunity and vaccination. Curr Mol Med 2002; 2: 507-524.
15. Trinchieri G. Immunobiology of interleukin-12. Immunol Res 1998; 17: 269-278.
16. + effector T cells and susceptibility to infectious diseases. Adv Exp Med Biol 1998; 452: 45-52.
17. Altare F, Durandy A, Lammas D et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 1998; 280: 1432-1435.
18. Lu H, Zhong G. Interleukin-12 production is required for chlamydial antigen-pulsed dendritic cells to induce protection against live Chlamydia trachomatis infection. Infect Immun 1999; 7: 1763-1769.
19. Roilides E, Tsaparidou S, Kadiltsoglou I, Sein T, Walsh TJ. Interleukin-12 enhances antifungal activity of human mononuclear phagocytes against Aspergillus fumigatus: implications for a gamma interferon-independent pathway. Infect Immun 1999; 67: 3047-3050.
20. Jiang C, Magee DM, Cox RA, Construction of a single-chain interleukin-12-expressing retroviral vector and its application in cytokine gene therapy against experimental coccidioidomycosis. Infect Immun 1999; 67: 2996-3001.
21. Brown K, Gao W, Alber S et al. Adenovirus-transduced dendritic cells injected into skin or lymph node prime potent simian immunodeficiency virus-specific T cell immunity in monkeys. J Immunol 2003; 171: 6875-6882.
22. Ranieri E, Herr W, Gambotto A et al. Dendritic cells transduced with an adenovirus vector encoding Epstein-Barr virus latent membrane protein 2B: a new modality for vaccination. J Virol 1999; 73: 10416-10425.
23. Mercier S, Gahery-Segard H, Monteil M et al. Distinct roles of adenovirus vector-transduced dendritic cells, myoblasts, and endothelial cells in mediating an immune response against a transgene product. J Virol 2002; 76: 2899-2911.
24. Ahuja SS, Reddick RL, Sato N et al. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol 1999; 163: 3890-3897.
25. Moll H, Berberich C. Dendritic cells as vectors for vaccination against infectious diseases. Int J Med Microbiol 2001; 291: 323-329.
26. Gilboa E, Nair SK, Lyerly HK. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immuno Immunother 1998; 46 82-87.
27. Kim JJ, Ayyavoo V, Bagarazzi ML et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. J Immunol 1997; 158: 816-826.
28. Sousa CR. Dendritic cells as sensors of infection. Immunity 2001; 14: 495-498.
29. Lanzavecchia A, Sallusto E Regulation of T cell immunity by dendritic cells. Cell 2001; 106: 263-266.
30. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg ML, Kalinski P. Development of Th1-inducing capacity in myeloid dendritic cells requires environmental instruction. J Immunol 2000; 164: 4507-4512.
31. Roilides E, Sein T, Roden M, Schaufele RL, Walsh TJ. Elevated serum concentrations of interleukin-10 in nonneutropenic patients with invasive aspergillosis. J Infect Dis 2001; 183: 518-520.
32. Grazziutti M, Przepiorka D, Rex JH, Braunschweig I, VadhanRaj S, Savary CA. Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus. Bone Marrow Transplant 2001; 27: 647-652.
33. Bozza S, Gaziano R, Spreca A et al. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. J Immunol 2002; 168: 1362-1371.
34. d'Ostiani CF, Del Sero G, Bacci A et al. Dendritic cells discriminate between yeasts and hyphae of the fungus Candida albicans: implications for initiation of T helper cell immunity in vitro and in vivo. J Exp Med 2000; 191: 1661-1674.
35. Ludewig B, Ehl S, Karrer U, Odermatt B, Hengartner H, Zinkernagel RM. Dendritic cells efficiently induce protective antiviral immunity. J Virol 1998; 72: 3812-3818.
36. Mbow ML, Zeidner N, Panella N, Titus RG, Piesman J. Borrelia burgdorferi-pulsed dendritic cells induce a protective immune response against tick-transmitted spirochetes. Infect Immun 1997; 65: 3386-3390.
37. Shaw JH, Grund VR, Durling L, Caldwell HD. Expression of genes encoding Th1 cell-activating cytokines and lymphoid homing chemokines by chlamydia-pulsed dendritic cells correlates with protective immunizing efficacy. Infect Immun 2001; 69: 4667-4672.
38. Berberich C, Ramirez-Pineda JR, Hambrecht C, Alber G, Skeiky YA, Moll H. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol 2003; 170: 3171-3179.
39. Curiel-Lewandrowski C, Mahnke K, Labeur M et al. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J Immunol 1999; 163: 174-183.
40. Kikuchi T, Crystal RG. Antigen-pulsed dendritic cells expressing macrophage-derived chemokine elicit Th2 responses and promote specific humoral immunity. J Clin Invest 2001; 108: 917-927.
41. Su H, Messer R, Whitmire W, Fischer E, Portis JC, Caldwell HD. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable Chlamydiae. J Exp Med 1998; 188: 809-818.
42. Bourguin I, Moser M, Buzoni-Gatel D et al. Murine dendritic cells pulsed in vitro with Toxoplasma gondii antigens induce protective immunity in vivo. Infect Immun 1998; 66: 4867-4874.
43. Barratt-Boyes SM, Zimmer MI, Harshyne LA et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J Immunol 2000; 164: 2487-2495.
44. De Vries IJ, Krooshoop DJ, Scharenborg NM et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003; 63: 12-17.
45. Kuribayashi K, Tsukiyama M, Takenaka T. Secretion patterns of Th1- and Th2-type cytokines in immune deviation caused by dendritic cells. Int Arch Allergy Immunol 1997; 114: 30-37.
46. Bacci A, Montagnoli C, Perruccio K et al. Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoietic transplantation. J Immunol 2002; 168: 2904-2913.
47. Bozza S, Gaziano R, Lipford GB et al. Vaccination of mice against invasive aspergillosis with recombinant Aspergillus proteins and CpG oligodeoxynucleotides as adjuvants. Microbes Infect 2002; 4: 1281-1290.
48. Bozza S, Perruccio K, Montagnoli C et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003; 102: 3807-3814.
49. Decken K, Kohler G, Palmer-Lehmann K et al. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun 1998; 55: 4994-5000.
50. Gilboa E. Immunotherapy of cancer with genetically modified tumor vaccines. Semin Oncol 1996; 23: 101-107.
51. Pisarev V, Yu B, Salup R, Sherman S, Altieri DC, Gabrilovich DI. Full-length dominant-negative survivin for cancer immunotherapy. Clin Cancer Res 2003; 9: 6523-6533.
52. Zhang L, Tang Y, Akbulut H, Zelterman D, Linton PJ, Deisseroth AB. An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells. Proc Natl Acad Sci USA 2003; 100: 15101-15106.
53. Grazziutti B, Przepiorka D, Rex JH, Braunschweig I, VadhanRaj S, Savary CA. Lymphocyte stimulation dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus. Bone Marrow Transplant 2001; 27: 647-652.
54. Zhang ZL, Zou WG, Luo CX et al. An armed oncolytic adenovirus system, ZD55-gene, demonstrating potent antitumoral efficacy. Cell Res 2003; 13: 481-489.
55. Inaba K, Inaba M, Romani N et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992; 176: 1693-1702.
56. Sisto F, Miluzio A, Leopardi O, Mirra M, Boelaert JR, Taramelli D. Differential cytokine pattern in the spleens and livers of BALB/c mice infected with Penicillium marneffei: protective role of gamma interferon. Infect Immun 2003; 71: 465-473.